AI assistant
Eledon Pharmaceuticals, Inc. — Director's Dealing 2019
May 22, 2019
33900_dirs_2019-05-22_bc1c2763-8e9d-4b1f-a617-7234c6e65d6a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Novus Therapeutics, Inc. (NVUS)
CIK: 0001404281
Period of Report: 2019-05-20
Reporting Person: FLESHER GREGORY J. (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-05-20 | Common Stock | S | 11701.00 | $1.9616 | Disposed | 159855.00 | Direct |
| 2019-05-21 | Common Stock | S | 2937.00 | $1.9114 | Disposed | 156918.00 | Direct |
Footnotes
F1: Shares were sold to cover the reporting person's taxes due on the vesting of restricted stock units.
F2: This transaction was executed in multiple trades at prices ranging from $1.90 to $2.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $1.90 to $1.945. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.